ArticleClinical and vaccine immunology : CVI2008
Evaluation of a commercial immunoblot, Helicoblot 2.1, for diagnosis of Helicobacter pylori infection.
Article in Clinical and vaccine immunology : CVI, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Non-invasive diagnostic tests for Helicobacter pylori infection.The Cochrane database of systematic reviews · 2018Pooled it
- Potential pathogenesis ofFuture science OA · 2026Article
- Calibrating multiplex serology for Helicobacter pylori.Diagnostic and prognostic research · 2025Article
- Statistical Models for High-Risk Intestinal Metaplasia with DNA Methylation Profiling.Epigenomes · 2024Article
- Diagnostic Testing Accuracy forMicroorganisms · 2023Article
- Performance of a Multiplex Serological Helicobacter pylori Assay on a Novel Microfluidic Assay Platform.Proteomes · 2017Article
- Reproductive factors, hormone use and gastric cancer risk: The Singapore Chinese Health Study.International journal of cancer · 2016Article
- Performances of Four Helicobacter pylori Serological Detection Kits Using Stool Antigen Test as Gold Standard.PloS one · 2016Article
- Diagnosis ofDiseases (Basel, Switzerland) · 2015Review
- Coffee intake and gastric cancer risk: the Singapore Chinese health study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Article
- H. pylori seropositivity before age 40 and subsequent risk of stomach cancer: a glimpse of the true relationship?PloS one · 2011Article
- Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection.World journal of gastroenterology · 2010Article
- Diagnostic Value of the Pylori DuoTect Test for Helicobacter pylori Detection in the Vietnamese Population.HelicobacterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The best method to diagnose Helicobacter pylori infection in different clinical situations is controversial. The aim of the study was to assess the performance of a commercial immunoblot, Helicoblot 2.1. The study comprised 215 patients, who were grouped according to the presence of H. pylori infection (assessed by two gastroscopies including histology with a median interval of 7.1 years, enzyme immunoassay [EIA]-based serology, and history of previous H. pylori infections and eradication therapies) into four categories: no H. pylori infection ever, previous infection, ongoing infection, and EIA seropositivity as the only marker of a possible previous infection. The sensitivity of Helicoblot 2.1 to show an ongoing or previous H. pylori infection was 100% and 92%, respectively. Helicoblot 2.1 was negative in only 80% of individuals with no evidence of present or previous infection but in 96% of patients 50 years of age or younger. The current infection marker of the immunoblot was positive in 49% of patients with successful H. pylori eradication therapy. After successful eradication therapy, Helicoblot 2.1 sustained positive results in 87% of patients, and CagA positivity was detected in 87% of patients with follow-up samples for more than 10 years after therapy. Helicoblot 2.1 is a sensitive and, among patients of ages 50 years or younger, a specific test in the primary diagnosis of H. pylori infection. However, it does not discriminate between past and current infections. It can be used in epidemiological studies assessing the role of H. pylori in different late sequelae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.